|
|
|
|
|
Expression of ENO3 and Its Effect on Sensitivity of Hepatocellular Carcinoma Cells to Oxaliplatin |
| CUI Honglei1, ZHANG Xiaodan2, GUO Danfeng2, YAN Zhiping2, GUO Wenzhi1, ZHANG Shuijun1 |
| 1. Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; 2. Henan Engineering Technology Research Center of Organ Transplantation, Zhengzhou 450052, China |
|
|
|
|
Abstract Objective To investigate the expression of ENO3 gene in hepatocellular carcinoma and its effect on the sensitivity of hepatocellular carcinoma cell lines to OXA, and to explore the possible mechanism. Methods qRT-PCR and immunohistochemical analysis were used to detect the expression of ENO3 in 48 pairs of hepatocellular carcinoma tissues and normal liver tissues. Overexpression plasmid was constructed and transfected into MHCC97H and HepG2 cells. The experiments were divided into empty group (Vector group), ENO3 overexpression group (ENO3 group), empty+OXA group (Vector+OXA group) and ENO3 overexpression+OXA group (ENO3+OXA group). The proliferation ability of MHCC97H and HepG2 cells were detected by CCK-8 assay and cell colony formation assay. The apoptosis rate was determined by flow cytometry assay. Protein expressions of Bcl-2, Bax and Caspase-3 were detected by Western blot assay. Results The expression of ENO3 was significantly decreased in hepatocellular carcinoma tissues, compared with normal liver tissues adjacent to the carcinoma. The expression of ENO3 gene in the ENO3 overexpression group was significantly higher than that in the empty group. Compared with the Vector+OXA group, cell viability was decreased, apoptosis rate was increased, Bcl-2 protein expression was decreased, Bax and Caspase-3 protein expression were increased in the ENO3+OXA group. Conclusion The expression of ENO3 is down-regulated in hepatocellular carcinoma tissues, and the overexpression of ENO3 can enhance the sensitivity of hepatocellular carcinoma cell lines to oxaliplatin by promoting cell apoptosis.
|
| Keywords
ENO3
Oxaliplatin
Hepatocellular carcinoma
Apoptosis
|
|
|
| Fund:National Natural Science Foundation of China (No. 81901571); China Postdoctoral Science Foundation (No. 2020M672265); Henan Provincial Medical Science and Technology Research Plan (No. SBGJ2018002) |
|
Issue Date: 17 May 2022
|
|
[1] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌
诊疗规范(2019年版)[J]. 中华肝脏病杂志, 2020, 28(2): 112-128.
[Bureau of Medical Administration, National Health Commission
of the People's Republic of China. Guidelines for diagnosis and
treatment of primary liver cancer in China (2019 edition)[J].
Zhonghua Gan Zang Bing Za Zhi, 2020, 28(2): 112-128. ]
[2] Wang Z, Zhou J, Fan J, et al. Oxaliplatin induces apoptosis in
hepatocellular carcinoma cells and inhibits tumor growth[J].
Expert Opin Investig Drugs, 2009, 18(11): 1595-1604.
[3] Chen S, Zhang K, Liu W, et al. Hepatic arterial infusion of
oxaliplatin plus raltitrexed in patients with intermediate and
advanced stage hepatocellular carcinoma: A phase Ⅱ, single-arm,
prospective study[J]. Eur J Cancer, 2020, 134: 90-98.
[4] 王妍, 谢晓莺, 陈荣新, 等. IL-17RA表达对肝细胞癌(HCC)患者
的预后意义及其对HCC细胞株生物学特性的影响[J]. 复旦学
报(医学版), 2019, 46(5): 625-630, 636. [Wang Y, Xie XY, Chen
RX, et al. The prognostic effect of IL-17RA for hepatocellular
carcinoma (HCC) patients and it's impact on the biological
characteristics of HCC cell lines[J]. Fudan Xue Bao(Yi Xue Ban),
2019, 46(5): 625-630, 636.]
[ 5 ] 中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗
指南(2022年版)[J]. 肿瘤防治研究, 2022, 49(3): 251-276.
[National Health Commission of the People’s Republic of China.
Standardization for diagnosis and treatment of primary hepatic
carcinoma (2022 edition)[J]. Zhong Liu Fang Zhi Yan Jiu, 2022,
49(3): 251-276.]
[6] Martinez-Balibrea E, Martínez-Cardús A, Ginés A, et al. Tumor-
Related Molecular Mechanisms of Oxaliplatin Resistance[J]. Mol
Cancer Ther, 2015, 14(8): 1767-1776.
[7] Wei TT, Lin YT, Tang SP, et al. Metabolic targeting of HIF-1alpha
potentiates the therapeutic efficacy of oxaliplatin in colorectal
cancer[J]. Oncogene, 2020, 39(2): 414-427.
[8] Jia X, Zhai T. Integrated Analysis of Multiple Microarray Studies
to Identify Novel Gene Signatures in Non-alcoholic Fatty Liver
Disease[J]. Front Endocrinol(Lausanne), 2019, 10: 599.
[9] Tarnopolsky MA. Myopathies Related to Glycogen Metabolism
Disorders[J]. Neurotherapeutics, 2018, 15(4): 915-927.
[10] Liu ZK, Zhang RY, Yong YL, et al. Identification of crucial genes
based on expression profiles of hepatocellular carcinomas by
bioinformatics analysis[J]. Peer J, 2019, 7: e7436.
[11] Zhong Y, Zhang J, Yu H, et al. Characterization and sub-cellular
localization of GalNAc-binding proteins isolated from human
hepatic stellate cells[J]. Biochem Biophys Res Commun, 2015,
468(4): 906-912.
[12] 陈渠发, 陈毅斌, 张锡迎, 等. PBK/TOPK在HCC组织中的表达
与HCC对奥沙利铂敏感性的关系研究[J]. 解放军预防医学杂
志, 2019, 37(3): 35-37. [Chen QF, Chen YB, Zhang XY, et al.
The relationship between the expression of PBK/TOPK in HCC
tissues and the sensitivity of HCC to oxaliplatin[J]. Jie Fang Jun
Yu Fang Yi Xue Za Zhi, 2019, 37(3): 35-37.]
[13] Park C, Lee Y, Je S, et al. Overexpression and Selective
Anticancer Efficacy of ENO3 in STK11 Mutant Lung Cancers[J].
Mol Cells, 2019, 42(11): 804-809.
[14] Pan X, Wu H, Chen G, et al. Prognostic Value of Enolase Gene
Family in Colon Cancer[J]. Med Sci Monit, 2020, 26: e922980.
[15] Tan Z, Lei Y, Xu J, et al. The value of a metabolic reprogrammingrelated
gene signature for pancreatic adenocarcinoma prognosis
prediction[J]. Aging(Albany NY), 2020, 12(23): 24228-24241.
[16] Huang JL, Fu YP, Gan W, et al. Hepatic stellate cells promote
the progression of hepatocellular carcinoma through microRNA-
1246-RORalpha-Wnt/beta-Catenin axis[J]. Cancer Lett, 2020,
476: 140-151.
[17] Flores-Ronero H, Ros U, Garcia-Saez AJ. Pore formation in
regulated cell death[J]. EMBO J, 2020, 39(23): e105753.
[18] Singh R, Letai A, Sarosie K. Regulation of apoptosis in health and
disease: the balancing act of BCL-2 family proteins[J]. Nat Rev
Mol Cell Biol, 2019, 20(3): 175-193. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
